Sign In
Section Navigation
Common TitleASPIRE
Official Title Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE)
Phase Phase III
ClinicalTrials.gov NCT02263326
Treatments
Dolutegravir-Lamivudine
Dolutegravir-Lamivudine Dovato

Dolutegravir-Lamivudine

Tradename:DovatoOther Names:DTG-3TCClass:Single-Tablet Regimens
Categories Treatment-ExperiencedDual Therapy
Funding
IndustryViiV Healthcare
References
  • Li JZ, Sax PE, Marconi VC, et al. No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis. 2019;6:ofz056.
    [PubMed Abstract]
  • Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018;66:1794-7.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.